Evidence map›Paper›PMID 38396445›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Prognostic Factors for Mortality in Hepatocellular Carcinoma at Diagnosis: Development of a Predictive Model Using Artificial Intelligence.

Pablo Martínez-Blanco, Miguel Suárez, Sergio Gil-Rojas, Ana María Torres, Natalia Martínez-García, Pilar Blasco, Miguel Torralba, Jorge Mateo

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pablo Martínez-BlancoGastroenterology Department, Virgen de la Luz Hospital, 16002 Cuenca, Spain.ORCID 0000-0001-5807-9653
Miguel SuárezGastroenterology Department, Virgen de la Luz Hospital, 16002 Cuenca, Spain.ORCID 0000-0002-9794-7449
Sergio Gil-RojasGastroenterology Department, Virgen de la Luz Hospital, 16002 Cuenca, Spain.
Ana María TorresMedical Analysis Expert Group, Institute of Technology, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain.
Natalia Martínez-GarcíaInternal Medicine Unit, Guadalajara University Hospital, 19002 Guadalajara, Spain.ORCID 0009-0008-3380-639X
Pilar BlascoDepartment of Pharmacy, General University Hospital, 46014 Valencia, Spain.
Miguel TorralbaInternal Medicine Unit, Guadalajara University Hospital, 19002 Guadalajara, Spain.ORCID 0000-0003-2166-7405
Jorge MateoMedical Analysis Expert Group, Institute of Technology, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) accounts for 75% of primary liver tumors. Controlling risk factors associated with its development and implementing screenings in risk populations does not seem sufficient to improve the prognosis of these patients at diagnosis. The development of a predictive prognostic model for mortality at the diagnosis of HCC is proposed.

methodsIn this retrospective multicenter study, the analysis of data from 191 HCC patients was conducted using machine learning (ML) techniques to analyze the prognostic factors of mortality that are significant at the time of diagnosis. Clinical and analytical data of interest in patients with HCC were gathered.

resultsMeeting Milan criteria, Barcelona Clinic Liver Cancer (BCLC) classification and albumin levels were the variables with the greatest impact on the prognosis of HCC patients. The ML algorithm that achieved the best results was random forest (RF).

conclusionsThe development of a predictive prognostic model at the diagnosis is a valuable tool for patients with HCC and for application in clinical practice. RF is useful and reliable in the analysis of prognostic factors in the diagnosis of HCC. The search for new prognostic factors is still necessary in patients with HCC.

Indexed as

albuminBCLChepatocellular carcinomamachine learningMilan criteriamortalityprognosis

Identifiers

PMID38396445
PMCPMC10888215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.